🍽️ Parabacteroides goldsteinii {Parabacteroides goldsteinii}

AI Engines For more Details: Perplexity Kagi Labs You

Check for interactions on Supp.AI | 📚 PubMed Citations

Data Contradictions — Limits of Certainity

Impacted of Parabacteroides goldsteinii {Parabacteroides goldsteinii} On Probiotics

Rank	Probiotic	Impact

Bacteria Impacted by Parabacteroides goldsteinii {Parabacteroides goldsteinii}

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

🧙?
📓 Direct Citations	👪👶 Indirect Citations	Taxonomy	Rank	Effect
0	1	Bacilli	class	Increases
0	1	Aerococcaceae	family	Increases
0	1	Carnobacteriaceae	family	Increases
0	1	Enterococcaceae	family	Increases
0	1	Lactobacillaceae	family	Increases
0	1	Leuconostocaceae	family	Increases
0	1	Odoribacteraceae	family	Increases
0	1	Streptococcaceae	family	Increases
1	0	Butyricimonas	genus	Increases
0	1	environmental samples	no rank	Increases
0	1	Lactobacillales incertae sedis	no rank	Increases
0	1	unclassified Butyricimonas	no rank	Increases
1	0	Lactobacillales	order	Increases
0	1	Butyricimonas faecalis	species	Increases
0	1	Butyricimonas faecihominis	species	Increases
0	1	Butyricimonas paravirosa	species	Increases
0	1	Butyricimonas phoceensis	species	Increases
0	1	Butyricimonas synergistica	species	Increases
0	1	Butyricimonas vaginalis	species	Increases
0	1	Butyricimonas virosa	species	Increases

Impact of Parabacteroides goldsteinii {Parabacteroides goldsteinii} on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition	Positive Impact	Negative Impact	Benefit Ratio Impact
Allergies	0.2		0.2
Allergy to milk products	1		1
Alopecia (Hair Loss)	0.6		0.6
Alzheimer's disease	0.2	0.2	0
Amyotrophic lateral sclerosis (ALS) Motor Neuron		0.2	-0.2
Ankylosing spondylitis	0.2	0.2	0
Anorexia Nervosa		1	-1
Antiphospholipid syndrome (APS)	0.6		0.6
Asthma	0.2	0.6	-2
Autism		1	-1
Barrett esophagus cancer	0.2		0.2
Bipolar Disorder	0.2	0.6	-2
Brain Trauma	0.6		0.6
Celiac Disease	0.8		0.8
Chronic Kidney Disease	0.2		0.2
Chronic Obstructive Pulmonary Disease (COPD)	0.8	0.2	3
Chronic Urticaria (Hives)		0.6	-0.6
Coagulation / Micro clot triggering bacteria	0.8		0.8
Cognitive Function	0.4	0.2	1
Colorectal Cancer		0.8	-0.8
Coronary artery disease		0.6	-0.6
COVID-19	0.2	1.2	-5
Crohn's Disease	0.2	1	-4
deep vein thrombosis	0.8		0.8
Depression	0.8	1.2	-0.5
Eczema	0.2		0.2
Endometriosis	0.2		0.2
Functional constipation / chronic idiopathic constipation	0.6	0.6	0
gallstone disease (gsd)		0.2	-0.2
Graves' disease	0.6	0.8	-0.33
Hashimoto's thyroiditis	0.2		0.2
High Histamine/low DAO	0.6		0.6
hyperglycemia	0.6		0.6
Hyperlipidemia (High Blood Fats)	0.4	0.2	1
hypertension (High Blood Pressure	0.6		0.6
Hypoxia		0.6	-0.6
IgA nephropathy (IgAN)	0.2		0.2
Inflammatory Bowel Disease	0.2		0.2
Insomnia	1		1
Irritable Bowel Syndrome	1	0.2	4
ischemic stroke	0.6		0.6
Liver Cirrhosis	0.8		0.8
Long COVID	0.8	1.6	-1
Lung Cancer	0.6		0.6
Metabolic Syndrome	0.8	0.6	0.33
Mood Disorders	0.6	1.2	-1
Multiple Sclerosis	1	0.6	0.67
neuropathic pain	0.6		0.6
Neuropathy (all types)	0.6		0.6
neuropsychiatric disorders (PANDAS, PANS)	0.2		0.2
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic		0.4	-0.4
Obesity	1		1
pancreatic cancer		0.4	-0.4
Parkinson's Disease	0.2	1.4	-6
Polycystic ovary syndrome		0.2	-0.2
primary biliary cholangitis	0.2	0.6	-2
Primary sclerosing cholangitis		0.6	-0.6
Psoriasis		0.2	-0.2
rheumatoid arthritis (RA),Spondyloarthritis (SpA)	0.6	0.8	-0.33
Schizophrenia	0.6	0.8	-0.33
Sleep Apnea	0.8		0.8
Systemic Lupus Erythematosus	0.2	1	-4
Type 2 Diabetes	0.4	0.6	-0.5
Ulcerative colitis	0.6	1.4	-1.33
Unhealthy Ageing	0.6		0.6

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]